GSK plc Form 6-K Summary
Business context and reporting period
Filed 1 October 2026 as a report by a foreign private issuer. The filing reports GSK’s issued share capital and total voting rights as of 30 September 2026; it is not a financial-results report.
Key figures
- Issued ordinary shares: 4,316,311,549, each with a nominal value of 31¼ pence.
- Ordinary shares held in treasury: 270,881,064.
- Total voting rights: 4,045,430,485. GSK states that shareholders may use this number as the denominator when assessing notification obligations under FCA disclosure rules.
Financial performance, changes, and outlook
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, comparative-period financial data, guidance, or management commentary on business outlook. It does not state how the share-capital figures changed from a prior period.
Facts for investors to verify
- Use 4,045,430,485 as the disclosed voting-rights denominator for the stated date, subject to any subsequent company announcements.
- Confirm the number of treasury shares and issued shares against later disclosures if calculating ownership or voting interests.
- For any financial or operating assessment, consult GSK’s relevant results filings; this 6-K contains no such performance data.